Ashland Shares Rise After Profit Widely Beats Expectations

Chemical maker Ashland posted a better-than-expected quarterly profit as it raised prices to counter rising raw material costs, sending its shares up more than 4% in premarket trading.

The company makes a wide range of specialty chemicals, including Valvoline oil as well as materials for the packaging and water purification industries. Its improving results offer a small hint on broader economic recovery.

The company's chief executive, James O'Brien, recently underwent surgery to fix a perforated colon. Ashland said last month that O'Brien would be away for up to three months. O'Brien is working on a limited basis after his surgery, a spokesman said on Tuesday.

For the second quarter ended on March 31, Ashland's net income came to $353 million, or $4.39 per share, including a $231 million gain from the sale of its distribution unit to private equity firm TPG Capital for $979 million cash. Excluding that and other one-time items, Ashland posted earnings of 86 cents per share. By that measure, analysts expected 77 cents, according to Thomson Reuters I/B/E/S. Year-earlier net income was $22 million, or 27 cents per share.

Revenue rose 9% to $1.56 billion. Analysts expected $1.49 billion. The cost of sales rose 14% to $1.14 billion.

Shares of Ashland were up 4.3% to $59.50 in trading before the market opened. The stock price has ranged from $42.77 to $63.69 in the past 52 weeks.

Company

Logo:

Ashland

500 Hercules Road Building 8145
19808 Wilmington, DE
US

Company contact







Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read